CCR7 and lung carcinoma: Intriguingly, despite the conserved expression of co-inhibitory molecules such as PD-L1 in CCR7+ DCs, the expression of the DC activation-associated marker LAMP3 is associated with improved prognosis in breast, lung cancer and metastatic melanoma12–15.